Neuren Pharmaceuticals LimitedASX: NEU

Neuren adds SYNGAP1-related disorder to NNZ-2591 pipeline

· Issued by Neuren Pharmaceuticals Limited

Filed with ASX · · 2 pages · English

Summary by 6ix AI

This disorder currently has no approved treatments and is caused by a genetic variant affecting neuronal communication. The company is focused on developing therapies for serious neurological disorders with limited treatment options.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Neuren Pharmaceuticals Limited on 6ix

Earlier from Neuren Pharmaceuticals

Later from Neuren Pharmaceuticals

All Neuren Pharmaceuticals news releases